Lion Street Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lion Street Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,550	Closed	-$202K	–	256
2023 Q2	$202K	Buy	+2,550	New	+$240K	0.07%	231
2022 Q3	–	Sell	-2,521	Closed	-$201K	–	133
2022 Q2	$201K	Buy	+2,521	New	+$201K	0.11%	149
2022 Q1	–	Sell	-2,569	Closed	-$226K	–	143
2021 Q4	$226K	Buy	+2,569	New	+$212K	0.11%	141
2020 Q2	–	Sell	-5	Closed	–	–	75
2020 Q1	$0	Buy	+5	New	+$431	﹤0.01%	429

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Lion Street Advisors's BMRN Position: Q3 2023 in Review

Lion Street Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 2,550 shares — an estimated $202K sold.

Lion Street Advisors first reported a position in BMRN in Q1 2020 and held it in 4 quarters. The position peaked at $226K in Q4 2021. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Lion Street Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Lion Street Advisors sold 2,550 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $202K.
Lion Street Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 4 quarters.
Lion Street Advisors's BioMarin Pharmaceuticals position peaked at $226K in Q4 2021.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Lion Street Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.